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The Big Ones That Got Away:
Omega-3 Meta-analysis Flawed
by Excluding the Biggest Fish Oil Trials
K wak et al
1(p686) state that “Our meta-analysis
showed insufficient evidence of a secondary
preventive effect of omega-3 fatty acid supple-
ments against overall cardiovascular events among
patients with a history of cardiovascular disease.” We
respectfully disagree with this conclusion. This meta-
analysis mainly included trials comprising only 50 to
550 patients with just 2 years or less of follow-up (the
point at which the survival curves started to diverge in
the Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico [GISSI] Heart Failure study2) in
10 of the 14 trials. In addition, 5 of the 14 trials were, in
fact, not truly placebo controlled but used olive oil as a
comparator. Kromhout et al3 used omega-3 fatty acids
in margarine spread over multiple pieces of toast per
day, which could nullify any beneficial effects of fish
oil. Most included trials were not powered to detect a
difference in cardiovascular outcomes (OMEGA4 and
the SU.FOL.OM3 [Supple´mentation en Folates et
Omega-3]5 studies had approximately 20% power to de-
tect a 25% benefit of omega-3 and the Alpha Omega
study3 [used just 380 mg/d of eicosapentanoic
aciddocosahexaenoic acid] had approximately half
the statistical power as the GISSI-Prevenzione study6).
Thus, a “lack of inclusion of sufficient trial data” should
not be interpreted as “insufficient evidence at prevent-
ing cardiovascular events.”
Excluded trials such as Diet and Reinfarction Trial
(DART),7 which randomized 2033 men after myocar-
dial infarction to fatty fish or 3 g of fish oil, showed a
significant 29% reduction in 2-year all-cause mortality
compared with those not so advised (P= .05) and a
16% reduction in the risk of ischemic heart disease
events. The GISSI-Prevention trial6 randomized 11 324
patients after myocardial infarction to 1 g of omega-3
fatty acids for 3.5 years, which significantly lowered
the risk of the primary end point (15% risk reduction
in nonfatal myocardial infarction, death, and stroke as
well as significant reductions in the risk of death
[20%], cardiovascular death [30%], and sudden car-
diac death [45%]). The Japan Eicosapentaenoic Acid
Lipid Intervention Study (JELIS)8 was a randomized,
blinded end point trial in 18 645 patients assigned to
1.8 g of eicosapentaenoic acid for 4.6 years. Omega-3
fatty acids caused relative risk reductions of 19% and
24% in major coronary events and unstable angina,
respectively. Furthermore, nonfatal coronary events
were significantly lower in the eicosapentaenoic acid
group compared with placebo.8
In conclusion, the meta-analysis performed by
Kwak et al1 is significantly flawed by inclusion of
negative poor quality, short-term studies, while
excluding positive larger and longer-term studies. We
believe that the findings of this meta-analysis should
be interpreted with caution.
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In reply
We appreciate the letter of DiNicolantonio et al in response
to our report1 in the Archives. We acknowledge that sev-
eral methodologic issues raised by DiNicolantonio et al are
important for our main conclusions.
First, regarding the small sample size and short fol-
low-up period, we stated in the limitations of the “Com-
ment” section1(p693) that
Fifth, most trials included in the present meta-analysis had a
small sample size of 59 to 500 participants and a short dura-
tion of treatment of less than 2 to 3 years. Further larger trials
are needed.
However, although we included trials with a small sample
size of participants, the number of total participants in the
meta-analysis was more than 20 000, which is regarded as
having enough power to detect a difference in cardiovascu-
lar outcomes.
Second, regarding the exclusion of the 5 trials with the
use of olive oil as a control group, whenwe performed a sub-
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group meta-analysis with excluding those 5 trials, no pre-
ventive effect of omega-3 fatty acid supplementation on over-
all cardiovascular events was observed (relative risk [RR],
0.94; 95%CI, 0.83-1.07). Also, when we performed ameta-
analysis without the trial by Kromhout et al2 that used mar-
garine spread, there was no preventive effect (RR, 0.98; 95%
CI, 0.86-1.11).
Third, the Diet and Reinfarction Trial (DART)3 that
DiNicolantonio et al mentioned is not a relevant trial for
our meta-analysis because it used only advice on an in-
crease in fatty fish intake, not omega-3 fatty acid supple-
mentation.
Last, regarding the exclusion of the Gruppo Italiano per
lo Studio della Sopravvivenza nell’Infarto Miocardico
(GISSI)-Prevenzione4 and JapanEicosapentaenoic Acid Lipid
Intervention Study (JELIS)5 in our analysis, we already ad-
dressed in the “Comment” section. Again, the main reason
that we excluded those 2 large randomized controlled trials
is that they used an open-label design without using place-
bos, which is liable to performance bias. For the readers who
have the same question, in our article1(p691) we already men-
tioned that
Whenweperformed ameta-analysiswith theGISSI-Prevenzione
trial[4] and the JELIS[5] in addition to the 14 trials included in
the present study, a preventive effect of omega-3 fatty acid
supplementation was not observed (RR, 0.95; 95% CI, 0.87-
1.03; I2=35.5%) (data not shown).
In conclusion, despite somemethodologic issues and limi-
tations, our meta-analysis indicates that there is a lack of
sufficient evidence of the secondary preventive effects of
omega-3 supplementation on cardiovascular disease. Fur-
ther larger randomized, double-blind, placebo-controlled
trials are needed to confirm our findings.
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Antipsychotic Drugs and Myocardial
Infarction in Patients With Dementia
P ariente et al
1 conducted a retrospective study of
prescription claims data and found that, in
elderly patients receiving anticholinesterase
medications, antipsychotic dispensing was associated
with an increased risk of myocardial infarction
only during the first 2 months following antipsychotic
initiation; in matched cohort and self-controlled
analyses, there was no statistically significant elevation
in infarction risk during subsequent periods,
extending to a year after antipsychotic initiation and
beyond.
Protopathic bias was briefly considered as an expla-
nation for the initial risk1; otherwise, the clinical signifi-
cance of the lack of later risk was not addressed in either
themain article1 or the accompanying commentary.2 This
is surprising because the finding actually implies pos-
sible cardiovascular safety of antipsychotic medication
in dementia. After all, if antipsychotic medication truly
elevates cardiovascular risks, the effects should be uni-
form across time or cumulative, rather than only during
the initial phase of treatment.
If antipsychotics truly raise cardiovascular risks at all
periods, an explanation for the apparent late safety is that
patients at high risk may not survive to contribute to the
risk in later exposure periods. Importantly, instead, an-
tipsychotics may truly be associated with only an initial
risk andwith an absence of risk during later periods. This
can happen if the indications for which they are pre-
scribed (eg, psychotic symptoms) are associatedwith state-
dependent cardiovascular risk factors (eg, agitation),
which attenuate or disappear (eg, because of antipsy-
chotic treatment) in latermonths. If so, antipsychotic use
may merely be a marker for the presence of cardiovas-
cular risk factors and not the reason for infarction; al-
ternately, antipsychotic medication may interact with
state-dependent risk factors through an unknownmecha-
nism to trigger a cardiovascular event. Either way, pro-
spective studies should examine whether state-
dependent risk factors exist andwhether such risk factors
are modifiable. Positive results could pave the way for
the safer use of antipsychotic medication for acute indi-
cations in dementia.
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